Premium
P4‐330: REPOSITIONING OF OBATOCLAX FOR IMAGING OF ALZHEIMER'S DISEASE
Author(s) -
Yang Jing,
Shao Yihan,
Ran Chongzhao
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.07.153
Subject(s) - in vivo , medicine , disease , genetically modified mouse , pharmacology , pathology , transgene , chemistry , biology , biochemistry , microbiology and biotechnology , gene
verage score LP 0.25 (-0.24, 0.73) HpSp -1.03 (-1.76, -0.31) Time -0.25 (-0.27, -0.23) LP * time 0.02 (-0.03, 0.06) HpSp * time -0.10 (-0.18, -0.02) emory score LP 0.38 (-0.40, 1.16) HpSp -1.40 (-2.57, -0.23) Time -0.38 (-0.41, -0.34) LP * time 0.03 (-0.04, 0.10) HpSp * time -0.14 (-0.26, -0.02) isuospatial score LP 0.18 (-0.12, 0.47) HpSp -0.54 (-1.00, -0.08) Time -0.07 (-0.09, -0.05) LP * time 0.01 (-0.03, 0.04) Background:Alzheimer’s disease (AD) is an emerging public health crisis that poses a huge societal burden, and cheap and reliable early screening for preventive treatment is urgently needed.Methods:We demonstrated that Obatoclax, a fluorescent drug that is undergoing phase III anti-cancer trial, could be re-positioned as an imaging agent for preliminary screening of AD via near infrared fluorescence ocular imaging (NIRFOI), due to the transparency of eyes. Results:We showed that Obatoclax could bind to amyloid b (Ab) species, including monomers, oligomers and fibril aggregates in solutions, and could be used to stain Ab plaques from brain slices of AD mice and AD patients. In vivo NIRFOI results suggested that NIRFOI with Obatoclax could differentiate transgenic AD mice (5XFAD) from age-matched wild type (WT) mice. Conclusions: We believe that NIRFOI with Obatoclax has the potential for early preliminary imaging screening of AD patients with a primary care setting in the future. HpSp * time -0.03 (-0.10, 0.04) xecutive functioning score P4-331 LONGITUDINAL COGNITIVE LP 0.03 (-0.31, 0.36) HpSp -0.49 (-1.00, 0.02) Time -0.17 (-0.19, -0.15) LP * time -0.00 (-0.04, 0.03) HpSp * time -0.02 (-0.09, 0.05) PERFORMANCE OFALZHEIMER’S DISEASE NEUROPATHOLOGICAL SUBTYPES IN THE RELIGIOUS ORDERS STUDYAND MEMORYAND AGING PROJECT anguage score LP 0.38 (-0.37, 1.13) HpSp -1.78 (-2.91, -0.66) Time -0.33 (-0.37, -0.30) LP * time 0.03 (-0.04, 0.11) HpSp * time -0.24 (-0.37, -0.11)